New Agents, Combinations, and Opportunities in the Treatment of Advanced and Early-Stage Colon Cancer

Surgical Clinics of North America

Volumn 86, Issue 4, 2006, Pages 1023-1043

  Natarajan, Neela ^a   Shuster, Todd D ^a  

^a LAHEY HOSPITAL AND MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; ANTINEOPLASTIC AGENT; BEVACIZUMAB; CAPECITABINE; CETUXIMAB; FLUOROPYRIMIDINE DERIVATIVE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; LEVAMISOLE; OXALIPLATIN;

ADVANCED CANCER; ALOPECIA; ANTINEOPLASTIC ACTIVITY; BLEEDING; BONE MARROW SUPPRESSION; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; COLON CANCER; CYTOPENIA; DIARRHEA; DRUG ACTIVITY; DRUG EFFICACY; DRUG ERUPTION; DRUG HYPERSENSITIVITY; DRUG POTENTIATION; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; DYSESTHESIA; EDEMA; GASTROINTESTINAL TOXICITY; HAND FOOT SYNDROME; HUMAN; HYPERTENSION; KIDNEY FAILURE; LIVER FUNCTION TEST; LIVER TOXICITY; META ANALYSIS; MUCOSA INFLAMMATION; NAUSEA; NEUTROPENIA; PRIORITY JOURNAL; PROGNOSIS; PROTEINURIA; REVIEW; RISK BENEFIT ANALYSIS; SENSORY DYSFUNCTION; SENSORY NEUROPATHY; SEPSIS; STOMATITIS; SYSTEMATIC REVIEW; THROMBOSIS; VASCULAR DISEASE; VEIN OCCLUSION;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COLONIC NEOPLASMS; HUMANS;

EID: 33746898685     PISSN: 00396109     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.suc.2006.06.002     Document Type: Review

References (66)

1. Jemal A., Murray T., Ward E., et al. Cancer statistics, 2005. CA Cancer J Clin 55 1 (2005) 10-30
2. O'Connell J.B., Maggard M.A., and Ko C.Y. Colon cancer survival rates with the new American Joint Committee on Cancer sixth edition staging. J Natl Cancer Inst 96 19 (2004) 1420-1425
3. Thirion P., Michiels S., Pignon J.P., et al. Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: an updated meta-analysis. J Clin Oncol 22 18 (2004) 3766-3775
4. Grothey A., Sargent D., Goldberg R., et al. Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment. J Clin Oncol 22 7 (2004) 1209-1214
5. Sobrero A., Guglielmi A., Grossi F., et al. Mechanism of action of fluoropyrimidines: relevance to the new developments in colorectal cancer chemotherapy. Semin Oncol 27 (2000) (5)(Suppl 10):72-7
6. Buroker T.R., O'Connell M.J., Wieand H.S., et al. Randomized comparison of two schedules of fluorouracil and leucovorin in the treatment of advanced colorectal cancer. J Clin Oncol 12 1 (1994) 14-20
7. Wang W.S., Lin J.K., Chiou T.J., et al. Randomized trial comparing weekly bolus 5-fluorouracil plus leucovorin versus monthly 5-day 5-fluorouracil plus leucovorin in metastatic colorectal cancer. Hepatogastroenterology 47 36 (2000) 1599-1603
8. de Gramont A., Bosset J.F., Milan C., et al. Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French intergroup study. J Clin Oncol 15 2 (1997) 808-815
9. Jager E., Heike M., Bernhard H., et al. Weekly high-dose leucovorin versus low-dose leucovorin combined with fluorouracil in advanced colorectal cancer: results of a randomized multicenter trial. Study Group for Palliative Treatment of Metastatic Colorectal Cancer Study Protocol 1. J Clin Oncol 14 8 (1996) 2274-2279
10. Iyer L., and Ratain M.J. Clinical pharmacology of camptothecins. Cancer Chemother Pharmacol 42 Suppl (1998) S31-S43
11. Cunningham D., Pyrhonen S., James R.D., et al. Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet 352 9138 (1998) 1413-1418
12. Rougier P., Van Custem E., Bajetta E., et al. Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer. Lancet 352 9138 (1998) 1407-1412
13. Saltz L.B., Cox J.V., Blanke C., et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med 343 13 (2000) 905-914
14. Douillard J.Y., Cunningham D., Roth A.D., et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 355 9209 (2000) 1041-1047
15. Patt YZ, Liebmann J, Diamandidis D, et al. Capecitabine (X) plus irinotecan (XELIRI) as first-line treatment for metastatic colorectal cancer (MCRC): final safety findings from a phase II trial. Presented at the 2004 American Society of Clinical Oncology Annual Meeting. New Orleans, June 5-8, 2004.
16. Van Custem E., Twelves C., Cassidy J., et al. Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study. J Clin Oncol 19 21 (2001) 4097-4106
17. Hoff P.M., Ansari R., Batist G., et al. Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study. J Clin Oncol 19 8 (2001) 2282-2292
18. Raymond E., Faivre S., Chaney S., et al. Cellular and molecular pharmacology of oxaliplatin. Mol Cancer Ther 1 3 (2002) 227-235
19. de Gramont A., Figer A., Seymour M., et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 18 16 (2000) 2938-2947
20. Giacchetti S., Perpoint B., Zindani R., et al. Phase III multicenter randomized trial of oxaliplatin added to chronomodulted fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer. J Clin Oncol 18 1 (2000) 136-147
21. Grothey A, Deschler B, Kroening H, et al. Phase III study of bolus 5-Fluorouracil (5-FU)/folinic acid (FA) (Mayo) vs weekly high-dose 24h 5-FU infusion/FA + oxaliplatin (OXA) (FUFOX) in advanced colorectal cancer (ACRC). Presented at the 2002 American Society of Clinical Oncology Annual Meeting. Orlando, May 18-21, 2002.
22. Rothenberg M.L., Oza A.M., Bigelow R.H., et al. Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: interim results of a phase III trial. J Clin Oncol 21 11 (2003) 2059-2069
23. Goldberg R.A., Sargent D.J., Morton R.F., et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 22 1 (2004) 23-30
24. Kabbinavar F., Hurwitz H.I., Fehrenbacher L., et al. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol 21 1 (2003) 60-65
25. Hurwitz H., Fehrenbacher L., Novotny W., et al. Bevacizumab plus irinotecan, fluorouracil and leucovorin for metastatic colorectal cancer. N Engl J Med 350 23 (2004) 2335-2342
26. Hochster HS, Welles L, Hart L, et al. Safety and efficacy of bevacizumab (Bev) when added to oxaliplatin/fluoropyrimidine (O/F) regimens as first-line treatment of metastatic colorectal cancer (mCRC): TREE 1 and 2 studies. Presented at the 2005 American Society of Clinical Oncology Annual Meeting. Orlando, May 13-17, 2005.
27. Giantonio BJ, Catalano PJ, Meropol NJ, et al. High dose bevacizumab improves survival when combined with FOLFOX4 in previously treated advanced colorectal cancer: results from the Eastern Cooperative Oncology Group (ECOG) study E 3200. Presented at the 2005 American Society of Clinical Oncology Annual Meeting. Orlando, May 13-17, 2005.
28. Saltz L, Rubin M, Hochster H, et al. Cetuximab (IMC-C225) plus irinotecan (CPT-11) is active in CPT-11 refractory colorectal cancer (CRC) that expresses epidermal growth factor receptor (EGFR). Presented at the 2001 American Society of Clinical Oncology Annual Meeting. San Francisco, May 12-15, 2001.
29. Cunningham D., Humblet Y., Siena S., et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 351 4 (2004) 337-345
30. Diaz Rubio E, Tabernero J, van Cutsem E, et al. Cetuximab in combination with oxaliplatin/5-fluorouracil (5-FU)/folinic acid (FA) (FOLFOX-4) in the first-line treatment of patients with epidermal growth factor receptor (EGFR)-expressing metastatic colorectal cancer: an international study Presented at the 2005 American Society of Clinical Oncology Annual Meeting. Orlando, May 13-17, 2005.
31. Seufferlein T, Dittrich C, Riemann J, et al. A phase I/II study of cetuximab in combination with 5-fluorouracil (5-FU)/folinic acid (FA) plus weekly oxaliplatin (L-OHP) (FUFOX) in the first-line treatment of patients with metastatic colorectal cancer (mCRC) expressing epidermal growth factor receptor (EGFR). Preliminary results. Presented at the 2005 American Society of Clinical Oncology Annual Meeting. Orlando, May 13-17, 2005.
32. Tournigand C., Andre T., Achille E., et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 22 2 (2004) 229-237
33. Kabbinavar F.F., Hambleton J., Mass R.D., et al. Combined analysis of efficacy: the addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer. J Clin Oncol 23 16 (2005) 3706-3712
34. In: Greene F.L., Balch C.M., Fleming I.D., et al. (Eds). AJCC cancer staging handbook. 6th edition (2002), Springer-Verlag, New York
35. Greene F.L., Stewart A.K., and Norton H.J. A new TNM staging strategy for node-positive (stage III) colon cancer: an analysis of 50,042 patients. Ann Surg 236 4 (2002) 416-421
36. NIH Consensus Conference. Adjuvant therapy for patients with colon and rectal cancer. JAMA 264 11 (1990) 1444-1450
37. Health tools: adjuvant systemic therapy for resected colon cancer. Available at: http://www.mayoclinic.com/calcs. Accessed February 1, 2006.
38. Adjuvant! for colon cancer. Available at: http://www.adjuvantonline.com. Accessed February 1, 2006.
39. Laurie J.A., Moertel C.G., Fleming T.R., et al. Surgical adjuvant therapy of large-bowel carcinoma: an evaluation of levamisole and the combination of levamisole and fluorouracil. The North Central Cancer Treatment Group and the Mayo Clinic. J Clin Oncol 7 10 (1989) 1447-1456
40. Moertel C.G., Fleming T.R., Macdonald J.S., et al. Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. N Engl J Med 322 6 (1990) 352-358
41. Haller DG, Catalano PJ, Macdonald JS, Mayer RJ. Fluorouracil (FU), leucovorin (LV) and levamisole (LEV) adjuvant therapy for colon cancer: four-year results of INT-0089. Presented at the 1997 American Society of Clinical Oncology Annual Meeting. Denver, May 17-20, 1997.
42. de Gramont A, Banzi M, Navarro M, et al. Oxaliplatin/5-FU/LV in adjuvant colon cancer: results of the international randomized MOSAIC trial. Presented at the 2003 American Society of Clinical Oncology Annual Meeting. Chicago, May 31-June 3, 2003.
43. Andre T., Boni C., Mounedji-Boudiaf L., et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 350 23 (2004) 2343-2351
44. de Gramont A, Boni C, Navarro M, et al. Oxaliplatin/5FU/LV in the adjuvant treatment of stage II and stage III colon cancer: efficacy results with a median follow-up of 4 years. Presented at the 2005 American Society of Clinical Oncology Annual Meeting. Orlando, May 13-17, 2005.
45. Sargent DJ, Wieand S, Benedetti J, et al. Disease-free survival (DFS) vs. overall survival as a primary endpoint for adjuvant colon cancer studies: individual patient data from 12,915 patients on 15 randomized trials. Presented at the 2004 American Society of Clinical Oncology Annual Meeting. New Orleans, June 5-8, 2004.
46. Wolmark N, Wieand HS, Kuebler JP, et al. A phase III trial comparing FULV to FULV + oxaliplatin in stage II or III carcinoma of the colon: results of NSABP protocol C-07. Presented at the 2005 American Society of Clinical Oncology Annual Meeting. Orlando, May 13-17, 2005.
47. Saltz LB, Niedzwiecki D, Hollis D, et al. Irinotecan plus fluorouracil/leucovorin (IFL) versus fluorouracil/leucovorin alone (FL) in stage III colon cancer (intergroup trail CALGB C89803). Presented at the 2003 American Society of Clinical Oncology Annual Meeting. Chicago, May 31-June 3, 2003.
48. Van Cutsem E, Labianca R, Hossfeld D, et al. Randomized phase III trial comparing infused irinotecan/5-fluorouracil (5-FU)/folinic acid (IF) versus 5-FU/FA (F) in stage III colon cancer patients (pts). (PETACC 3). Presented at the 2005 American Society of Clinical Oncology Annual Meeting. Orlando, May 13-17, 2005.
49. Ychou M, Raoul J, Douillard J, et al. A phase III randomized trial of LV5FU2 + CPT-11 vs. LV5FU2 alone in adjuvant high risk colon cancer (FNCLCC Accord02/FFCD9802). Presented at the 2005 American Society of Clinical Oncology Annual Meeting. Orlando, May 13-17, 2005.
50. Twelves C., Wong A., Nowacki M.P., et al. Capecitabine as adjuvant treatment for stage III colon cancer. N Engl J Med 352 26 (2005) 2696-2704
51. International Multicentre Pooled Analysis of B2 Colon Cancer Trials (IMPACT B2) Investigators. Efficacy of adjuvant fluorouracil and folinic acid in B2 colon cancer. J Clin Oncol 17 5 (1999) 1356-1363
52. Mamounas E., Wieand S., Wolmark N., et al. Comparative efficacy of adjuvant chemotherapy in patients with Dukes' B versus Dukes' C colon cancer: results from four National Surgical Adjuvant Breast and Bowel Project adjuvant studies (C-01, C-02, C-03, and C-04). J Clin Oncol 17 5 (1999) 1349-1355
53. Gray RG, Barnwell J, Hills R, et al, for the QUASAR Collaborative Group. QUASAR: a randomized study of adjuvant chemotherapy (CT) vs. observation including 3238 colorectal cancer patients. Presented at the 2004 American Society of Clinical Oncology Annual Meeting. New Orleans, June 5-8, 2004.
54. Benson III A.B., Schrag D., Somerfield M.R., et al. American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer. J Clin Oncol 22 16 (2004) 3408-3419
55. Engstrom P. Update: NCCN colon cancer clinical practice guidelines. J Natl Compr Canc Netw 3 Suppl 1 (2005) S25-S28
56. Gryfe R., Kim H., Hsieh E.T., et al. Tumor microsatellite instability and clinical outcome in young patients with colorectal cancer. N Engl J Med 342 2 (2000) 69-77
57. Shibata D., Reale M.A., Lavin P., et al. The DCC protein and prognosis in colorectal cancer. N Engl J Med 335 23 (1996) 1727-1732
58. Choti M.A., Sitzmann J.V., Tiburi M.F., et al. Trends in long-term survival following liver resection for hepatic colorectal metastases. Ann Surg 235 6 (2002) 759-766
59. Langer B, Bleiberg H, Labianca R, et al. Fluorouracil (FU) plus l-leucovorin (l-LV) versus observation after potentially curative resection of liver or lung metastases from colorectal cancer: results of the ENG (EORTC/NCIC CTG/GIVIO) randomized trial. Presented at the 2002 American Society of Clinical Oncology Annual Meeting. Orlando, May 18-21, 2002.
60. NCCN practice guidelines on treatment of colon cancer, version 2. 2006. Available at: http://www.nccn.org/professionals/physician_gls/PDF/colon.pdf. Accessed January 15, 2006.
61. Kemeny N., Huang Y., Cohen A.M., et al. Hepatic arterial infusion of chemotherapy after resection of hepatic metastases from colorectal cancer. N Engl J Med 341 27 (1999) 2039-2048
62. Delaunoit T., Alberts S.R., Sargent D.J., et al. Chemotherapy permits resection of metastatic colorectal cancer: experience from Intergroup N9741. Ann Oncol 16 3 (2005) 425-429
63. Bilchik A.J., Poston G., Curley S.A., et al. Neoadjuvant chemotherapy for metastatic colon cancer: a cautionary note. J Clin Oncol 23 36 (2005) 9073-9078
64. Fernandez F.G., Ritter J., Goodwin J.W., et al. Effect of steatohepatitis associated with irinotecan or oxaliplatin pretreatment on resectability of hepatic colorectal metastases. J Am Coll Surg 200 6 (2005) 845-853
65. Ribic C.M., Sargent D.J., Moore M.J., et al. Tumor microsatellite instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N Engl J Med 349 3 (2003) 247-257
66. Desch C.E., Benson III A.B., Somerfield M.R., et al. Colorectal cancer surveillance: 2005 update of an American Society of Clinical Oncology practice guideline. J Clin Oncol 23 33 (2005) 8512-8519